Witryna1 mar 2024 · All subjects were required to be responding to their current therapy, defined as at least a minimal response by international myeloma working group (IMWG) criteria, but have some persistent detectable disease … Witryna31 maj 2024 · Note: IMWG criteria defines refractory disease as disease progression on or within 60 days of a therapy Note: Induction treatment with or without hematopoietic stem cell transplant and with or without maintenance is considered a single regimen Documented measurable disease including at least one or more of the following criteria:

Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: …

Witryna14 kwi 2024 · Patients with ATC, BTC, GIST and ASI had at least one measurable lesion disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 (ref. 50) outside of a prior ... WitrynaFor the more than 3% of myeloma patients who have non-secretory or oligosecretory disease, and for the majority of patients with AL amyloidosis (AL), the traditional methods of measuring circulating monoclonal immunoglobulins (electrophoresis, immunoelectrophoresis, immunofixation electrophoresis, and nephelometric … drayton peterborough

FDA Grants FTD to Off-the-Shelf CAR T in R/R Multiple Myeloma

Witryna21 kwi 2010 · Recently, the IMWG Response Criteria were updated to add a more detailed evaluation of deep response, including Minimal Residual Disease (MRD) … WitrynaDetection of minimal residual disease in bone marrow Bone marrow examination has been the cornerstone of disease assessment in the absence of a measurable … Witryna21 maj 2024 · IMWG response criteria; Multiple myeloma response assessment (IMWG criteria) Multiple myeloma minimal residual disease assesment (IMWG criteria) ... drayton phone number